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Abstract 
A single contrast agent that offers whole-body non-invasive imaging along with the superior sensitivity 
and spatial resolution of surface-enhanced resonance Raman scattering (SERRS) imaging would allow 
both pre-operative mapping and intraoperative imaging and thus be highly desirable. We hypothesized 
that labeling our recently reported ultrabright SERRS nanoparticles with a suitable radiotracer would 
enable pre-operative identification of regions of interest with whole body imaging that can be rapidly 
corroborated with a Raman imaging device or handheld Raman scanner in order to provide high 
precision guidance during surgical procedures. Here we present a straightforward new method that 
produces radiolabeled SERRS nanoparticles for combined positron emission tomography (PET)-SERRS 
tumor imaging without requiring the attachment of molecular chelators. We demonstrate the utility of 
these PET-SERRS nanoparticles in several proof-of-concept studies including lymph node (LN) tracking, 
intraoperative guidance for LN resection, and cancer imaging after intravenous injection. We anticipate 
that the radiolabeling method presented herein can be applied generally to nanoparticle substrates of 
various materials by first coating them with a silica shell and then applying the chelator-free protocol. 
Key words: Intrinsic radiolabeling, Surface-enhanced resonance Raman scattering, SERS, Positron emission 
tomography, in vivo, Imaging. 
Introduction 
High-precision intraoperative imaging is 
necessary to delineate the true extent of tumor 
borders and identify the presence of multiple cancer 
foci or micrometastases. Failure to remove these 
malignant cells is a major reason for local recurrences 
and metastatic spread [1]. We previously 
demonstrated that the new generations of 
surface-enhanced resonance Raman scattering 
(SERRS) nanoparticles we have developed enable the 
visualization of the exact extent of malignant and 
even premalignant lesions after intravenous injection 
in many different mouse models, with microscopic 
accuracy [2-10]. Unlike conventional fluorescent 
imaging agents, SERRS nanoparticles exhibit 
exceptionally low limits of detection, resistance to 
photobleaching, unambiguous spectral signatures, 
and high multiplexing capabilities [2-4]. There is an 
increasing intererest in gold nanoparticles as a 
platform for cancer marker detection [11]. Our 
recently reported surfactant-free synthesis method of 
the gold nanoparticle cores should further aid in 
developing nontoxic SERRS nanoparticles with the 
potential for clinical translation [12, 13]. In contrast to 
fluorescence imaging agents [14], the unique 
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spectrum of SERRS nanoparticles does not exist in vivo 
and its specificity is therefore not affected by 
autofluorescence. The SERRS spectra serve as 
molecular fingerprints for optical imaging with very 
high signal-to-background ratios [7]. After resection 
under white-light, we were able to show that residual 
cancer can be visualized with SERRS imaging with 
tumor deposits as small as 100 µm being detectable, 
thereby minimizing the risk that cancer is left behind 
during surgery [4, 9, 15]. The increased precision of 
imaging the true extent of cancerous spread could 
markedly reduce the need for unnecessary resection 
of surrounding healthy tissue. It could also enable 
surgeries that are presently deemed unfeasible due to 
the proximity of adjacent crucial structures such as 
nerves or blood vessels, and allow minimally invasive 
and robotically assisted surgical approaches in 
situations where currently open surgical approaches 
are required. Furthermore, SERRS nanoparticles 
naturally accumulate in the reticuloendothelial 
system (RES), which has enabled advances in the 
intraoperative imaging of cancers involving the liver 
and lymph nodes [16-18].  
Although SERRS imaging has many advantages, 
it does not allow for preoperative surgical planning. 
Moreover, the high-resolution SERRS imaging 
necessary to observe small cancerous deposits limits 
the amount of tissue that can be imaged in an 
acceptable time frame during surgical procedures. 
These challenges can be overcome by the introduction 
of a complementary whole-body imaging modality 
that enables rapid pre-operative scans to serve as a 
roadmap to localize the macroscopic distribution of 
the tumors deep within organs. Given the very low 
injected dose of SERRS nanoparticles (<100 fmol/g), 
the most important consideration in a complimentary 
whole-body imaging modality is the limit of 
detection. Thus, positron emission tomography (PET), 
which has a sensitivity in the range of 10-11 – 10-12 M, 
would represent an ideal complementary imaging 
modality for SERRS nanoparticles [19]. 
In vivo imaging of PET-active SERRS 
nanoparticles (PET-SERRS NPs) for clinical 
applications has not yet been demonstrated. A 
previous report of Raman nanoparticle radiolabeling 
describes the attachment of 64Cu to silica via a 
molecular chelator, but did not demonstrate the 
serum stability of the radiolabeled probe [20]. We note 
that 64Cu can attach to silica under conditions similar 
to those reported by the authors, albeit weakly with 
poor serum stability [21]. Thus, competition for 
radionuclide binding by the nanoparticle itself 
complicates efforts to perform traditional 
molecular-based chelation and requires further 
characterization to demonstrate stable radiolabeling.  
The conventional molecular approach to 
radionuclide chelation presents several additional 
difficulties. First, the coordination chemistry changes 
significantly for different radionuclides, such that a 
molecule which chelates one species may fail to 
chelate many others. Moreover, some isotopes do not 
currently have established, reliable molecular 
chelators [22]. Secondly, the nanoparticles may not be 
stable under the conditions necessary for molecular 
chelation of radioisotopes, such as high temperatures 
and low or high pH. Even when a molecular chelator 
can be incorporated onto a nanoparticle surface, 
undesired side effects may occur, such as changes to 
the nanoparticle pharmacokinetics. Furthermore, the 
molecular chelators can be stripped from the 
nanoparticle surface in vivo, such that the imaging 
(e.g., positron emission tomography, single-photon 
emission tomography, etc.) and biodistribution 
studies do not correspond to the true distribution of 
the nanoparticles [23, 24]. In principle, these 
shortcomings could be overcome by a suitable 
chelator-free approach to SERRS nanoparticle 
radiolabeling, but to our knowledge no such method 
currently exists. 
Chelator-free intrinsic radiolabeling has been 
demonstrated in various systems, such as iron oxide 
and metal nanoparticles. Established approaches to 
intrinsic radiolabeling include direct synthesis from 
radioactive precursors [25], exploitation of specific 
trapping effects [26, 27], heterogeneous cation 
exchange reactions [28], and heat-induced 
coordination of radioactive metal cations [29, 30]. We 
recently showed that silica nanoparticles (i.e., without 
a gold core and free of molecular chelators) can bind 
89Zr, 68Ga, 90Y, 111In, 177Lu, and 64Cu with stability 
proportional to the oxophilicity of the radiometal ion 
[31]. Subsequently, we demonstrated that the addition 
of sulfur to silica nanoparticle surfaces allows stable 
radiolabeling of softer, more thiophilic radiometal 
ions such as 64Cu [21]. Chelator-free radiolabeling has 
also been demonstrated with mesoporous silica 
nanoparticles by others [32]. Accordingly, we 
hypothesized that intrinsic radiolabeling of our 
SERRS nanoparticles could be achieved by optimizing 
for incorporation of radionuclides into the silica shell. 
We identified the short-lived PET tracer 68Ga (t1/2 
= 68 min) as the ideal candidate for the radiolabeling 
of SERRS nanoprobes, due to i) its oxophilicity, ii) the 
fact that it is readily available from commercial 
generators, and iii) its relatively low radiation dose to 
healthy tissue resulting from its short half-life [31, 33]. 
The consideration of radiation dose to healthy tissue 
is particularly important for nanoparticle imaging 
agents because nanoparticle preparations are 
sequestered to a significant degree by the RES [34]. 
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Because of the short circulation time of these 
nanoprobes, 68Ga is optimal for imaging at the 
relevant pharmacokinetic time points (i.e. out to 3 
hours). The 68-minute half-life ensures that 68Ga is 
sufficiently decayed over the course of eight hours to 
allow SERRS imaging intraoperatively without the 
potential issue of exposure to radioactivity. We note, 
however, that the ideal radionuclide will vary 
depending upon the application, and that 
consideration of the half-life, mechanism of decay 
(e.g., positron emission necessary for PET), expected 
dose to healthy or diseased tissue, and coordination 
chemistry is necessary. 
Results and Discussion 
We first attempted to radiolabel SERRS 
nanoparticles with 68Ga by directly applying the 
protocol we had established using pure silica 
nanoparticles [31]. The SERRS nanoparticles consist of 
a gold core of ∼60 nm diameter, which is coated with a 
Raman reporter dye and a ∼30 nm thick silica shell [3, 
4]. We hypothesized that exposure to 68Ga under the 
proper reaction conditions would generate 
intrinsically radiolabeled SERRS nanoparticles with 
68Ga distributed throughout the silica shell (Fig. 1, 2). 
We performed a purified elution of 68Ga from the 
68Ge/68Ga generator with 0.2 N HCl followed by 68Ga 
trapping on a cartridge, which was then eluted after 
washing using 0.5 M potassium hydroxide (KOH). 
This was followed by neutralization with 
hydrochloric acid (HCl) or glacial acetic acid to 
achieve pH = 7.0-7.5 [35]. In contrast to our previous 
work with pure silica nanoparticles, the silica shell of 
SERRS nanoparticles became extremely porous and 
even disintegrated entirely for some nanoparticles 
upon exposure to the 68Ga solution (Fig. S1). 
Consequently, the radiolabeling was unsuccessful. 
The decreased stability of the SERRS 
nanoparticle silica shell compared to a pure silica 
nanoparticle is likely a consequence of their different 
synthetic conditions. In order to selectively generate 
silica shells around gold nanoparticles, the 
homogeneous nucleation of silica must be sufficiently 
disfavored such that heterogeneous nucleation and 
growth (i.e., shell formation) occurs, but formation of 
free silica nanoparticles is minimized. This is achieved 
by decreasing the rate of hydrolysis and condensation 
of silica precursors, for example by decreasing the 
water concentration during synthesis [36]. Decreased 
hydrolysis rates lead to more Si-O-Si broken bonds in 
the early stages of silica oligomerization and 
densification because the ethoxy groups of tetraethyl 
orthosilicate (TEOS) are not completely hydrolyzed 
[37-39]. Accordingly, homogenous nucleation is slow, 
but the gold nanoparticles provide surfaces to 
catalyze the condensation and aggregation reactions 
at the beginning of silica formation, thus enabling 
preferential nucleation (Fig. S2). However, the 
incomplete hydrolysis of silica precursors leads to 
broken Si-O-Si bonds within the amorphous silica 
structure and greater susceptibility to degradation 
[38]. Strategies must be developed, therefore, to 
render the radiolabeling procedure less harsh. 
 
 
Figure 1. Chelator-free radiolabeling of SERRS nanoparticles. 68Ga3+ is obtained from a 68Ge/68Ga generator via direct elution with HCl, rather than purified 
elution in KOH. The eluent is neutralized by addition of NH4OH with the hypothesized net effect that K+ cations that catalyze silica dissolution are replaced by NH4+ 
cations that leave the silica shells intact. The 68Ga-labeled PET-SERRS NPs are then easily purified by centrifugation. 
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Figure 2. Schematic of a resulting PET-SERRS nanoparticle. The 
PET-SERRS nanoparticle is comprised of a gold nanoparticle core, an adsorbed 
layer of Raman active molecules (IR-780), and a silica shell with a radionuclide 
(68Ga) embedded throughout. 
 
Since the rate of silica dissolution is catalyzed by 
the presence of potassium ions, we hypothesized that 
a radiolabeling procedure free of potassium would be 
less damaging to the silica shells [40]. Rather than 
eluting the 68Ga generator followed by 68Ga trapping 
on a cartridge and subsequent elution with KOH, we 
directly eluted the generator with 0.1 N HCl and 
neutralized the eluent with ammonium hydroxide 
(NH4OH) (see Methods for details) (Fig. 1). Because 
the NH4+ cations are softer and bulkier than K+, we 
hypothesized that they would not intercalate into the 
silica matrix as well; additionally, the ionic strength of 
the 68Ga solution is decreased using this strategy. The 
SERRS nanoparticles (10 nM nanoparticle 
concentration, 3.52 x 109 g/mol molar mass, 100 μL, 
pH = 8.5) were incubated with the 68Ga solution (100 
µL, 37 MBq (1.0 mCi), pH = 7.0-7.5) for 45 minutes at 
70 °C, then characterized by instant thin layer 
chromatography (iTLC), size exclusion (SE) filtration, 
transmission electron microscopy (TEM), dynamic 
light scattering, and zeta potential analysis. 
Radiolabeling was tested at pH = 7.4 as well as pH = 
8.5 and compared to a free 68Ga control that contained 
no nanoparticles. The radiochemical yield (non-decay 
corrected) was 90.92 +/-1.56% and 95.14 +/- 3.43% for 
pH = 7.4 and pH = 8.5, respectively, while the molar 
activity was 20-100 Ci/µmol of NPs. Radiochemical 
yield was calculated as the amount of radioactivity 
bound to the NP after purification via centrifugal 
pelleting over the total radioactivity (supernatant plus 
NP radioactivity). These controls are necessary, as 
macroscale gallium solutions at neutral pH may result 
in colloid formation; however, radiochemical (i.e. < 
nanomolar) concentrations of gallium in buffer 
precludes colloid formation [41]. 
Comparison of TEM images before and after 
radiolabeling revealed that the stability of the silica 
shells was greatly improved compared to the prior 
radiolabeling procedure which included the presence 
of K+ ions (Fig. 3A-B vs. Fig. S1). However, the 
porosity of the silica still increased and the shell 
thickness decreased by approximately 7 nm according 
to dynamic light scattering (Tables S1, S2). 
Nonetheless, the intensity of the SERRS spectrum did 
not decrease and the 68Ga radioactivity remained 
associated with the nanoparticles (Fig. 3C-D, Fig. S3). 
Although iTLC suggested a minor degree of 68Ga 
detachment after 3 h in 50 % fetal bovine serum (Fig. 
3D), the overall stability of the radiolabeling was 
sufficient to move forward with in vivo experiments. 
We note that successful radiolabeling with 68Ga was 
achieved at 25 °C after only 5 minutes of incubation 
with SERRS nanoparticles (Fig. S4), but did not 
demonstrate sufficient lasting stability of 
radiolabeling so the 70 °C/45 minutes-protocol was 
used for the remainder of the experiments. 
The PET-SERRS NPs were evaluated in vivo by 
lymph node imaging near the periphery of an 
orthotopic 4T1 breast cancer tumor. Lymph node 
imaging is especially important for the identification 
of sentinel lymph nodes, which are routinely excised 
and examined by pathology in clinical practice to 
determine if lymphatic metastases exist [10]. Because 
the location of the primary draining lymphatic vessel 
cannot be determined by visual inspection, sentinel 
lymph node imaging is performed clinically by 
injection of a contrast agent in and around a tumor 
[42]. We previously showed that both radiolabeled 
silica nanoparticles and SERRS NPs can identify 
sentinel lymph nodes separately [31, 43], but the 
combined pre- and intra-operative imaging with a 
single PET-SERRS imaging agent has not yet been 
demonstrated. The PET-SERRS NPs were injected 
subcutaneously at the tumor periphery and into the 
tumor itself. PET imaging 4 h post-injection revealed 
that much of the signal remained concentrated near 
the tumor, suggesting that most of the PET-SERRS 
nanoparticles had not migrated from the injection site. 
Notably, the cervical lymph node can be visualized 
using both PET and Cerenkov imaging with strong 
contrast at the 4 h time point (Fig. 4A, Fig. S5). As 
Cerenkov luminescence (CL) intensity correlates with 
the velocity of the charged particle, the high positron 
energy of 68Ga (βmax= 1.9 MeV) results in greater CL 
compared to radionuclides such as 18F [44, 45]. 
Although the axillary LN is the sentinel node for 
murine breast tissue, the size and location of the 
implanted tumor obscures the axillary LN in the small 
anatomical dimensions of a mouse. The cervical LN 
drains multiple regions, including the upper 
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extremities. The accumulation of PET-SERRS 
nanoparticles in the cervical LN occurs because one or 
more peripheral injection sites falls into its draining 
pathway [46, 47]. The cervical LN imaging illustrates 
that LN tracking can be achieved in vivo with 
PET-SERRS NPs. 
Intraoperative imaging of the cervical LN 
confirmed the presence of PET-SERRS NPs via Raman 
spectroscopy. The characteristic Raman spectrum of 
the PET-SERRS nanoparticles is detectable with a 
handheld Raman scanner (Figure 4B, C) [6], and 
enables near real-time analysis of the presence of 
PET-SERRS NPs. Using the handheld scanner, we 
identified the presence of the PET-SERRS NP 
fingerprint spectrum in the regions that also exhibited 
PET contrast, confirming that the PET-SERRS 
nanoparticles remained intact after subcutaneous 
injection and migration through the lymphatic 
channels. The handheld Raman scanner was used to 
guide surgical resection of the cervical LN, first by 
locating it in vivo, and then by confirming that all 
SERRS-positive tissue had been removed. 
Post-operative SERRS imaging was performed with 
the Raman imaging system to corroborate the 
handheld scanner results, and indeed showed that the 
lymph node had been completely resected (Fig. S6). 
Because the PET-SERRS nanoparticles naturally 
accumulate in the RES, they should be well suited for 
imaging cancers of the liver. In particular, the high 
uptake of nanoparticles in healthy RES tissue and 
comparatively much lower uptake of nanoparticles in 
cancerous tissue has proven sufficient to delineate 
tumors in vivo [48, 49]. Because the cancerous regions 
should contain fewer PET-SERRS NPs than the 
surrounding liver tissue, the presence of cancer is 
expected to manifest in filling defects (i.e., regions of 
little to no signal, surrounded by regions of high 
signal) with both PET and SERRS imaging. A first 
proof-of-principle of this concept for non-radiolabeled 
SERRS nanoparticles was recently shown [16]. 
 
 
 
Figure 3. Characterization of PET-SERRS nanoprobes. (A) Transmission electron microscopy image of PET-SERRS nanoparticles before radiolabeling with 
68Ga. (B) Transmission electron micrograph of PET-SERRS nanoparticles after radiolabeling with 68Ga at 70 °C for 45 minutes. (C) SERRS spectrum of PET-SERRS 
nanoparticles after radiolabeling at 70 °C for 45 minutes. The characteristic profile of IR-780 is unchanged and the intensity has not decreased. (D) Instant thin layer 
chromatography results of SERRS nanoparticle radiolabeling compared to free 68Ga. The percentage of 68Ga bound is determined by integrating the signal at the origin 
and dividing by the total integrated signal (see methods). 
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Figure 4. Lymph node tracking with PET-SERRS nanoparticles. (A) PET-CT image 4 h after the 68Ga-labeled PET-SERRS nanoparticles were injected around 
the periphery of an orthotopic 4T1 breast tumor. A lymph node can be clearly visualized away from the injection sites (arrowhead). (B) SERRS spectrum of 
PET-SERRS nanoparticles can be tracked in vivo with a handheld Raman scanner. The cervical LN exhibits the characteristic Raman spectrum of the PET-SERRS 
nanoparticle, which are not present outside of the LN. Accordingly, a quick handheld scan can be performed to guide location and resection of the LN. (C) After 
resection, the handheld scanner can be used to confirm that the SERRS spectrum is only detected in the excised tissue, indicating clean margins in the resection bed. 
 
  
 
 
Figure 5. Pre-operative staging and intraoperative imaging of liver cancer using PET-SERRS nanoparticles. (A) PET-CT image of tumor-bearing mouse reveals 
clear filling defects in the liver (arrows) after injection with PET-SERRS nanoparticles. (B) Intraoperative white light image of the liver from the mouse imaged in (A). Some of the 
tumors are visible by naked eye due to their large size and differential color. The location of the tumors matches the filling defects of the PET scan. (C) Maximum intensity 
projection (MIP) of the PET imaging data, showing healthy liver (high signal) and filling defects corresponding to tumors. (D) SERRS imaging of the liver provides a high-resolution, 
intraoperative map of normal liver (high SERRS signal) and location and extent of the tumors (signal voids). The correlation between PET signal and SERRS signal indicates that 
the nanoparticles remain intact and active in vivo. (E) Overlay of photograph and SERRS map shows that the filling defects in the SERRS signal correspond to cancer. 
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In order to test whether or not the 68Ga would 
remain bound to the SERRS NPs in vivo after 
intravenous injection, we injected a wild type mouse 
with PET-SERRS NPs (150 μL, 10 nM nanoparticles, 
500 μCi, 18.5 MBq 68Ga) and followed the distribution 
of PET signal on positron emission 
tomography-computed tomography (PET-CT). After 
only 5 minutes, the PET signal was already localized 
to the liver according to PET-CT (Fig. S7). This 
concentration of PET signal in the liver is consistent 
with the observed biodistribution of SERRS 
nanoparticles and with the biodistribution of 
68Ga-labeled silica nanoparticles [4, 31]. Moreover, this 
signal distribution is not consistent with the 
biodistribution of free 68Ga (i.e., not bound by a 
chelator), which shows high blood and bladder signal 
and relatively low RES signal at 1 and 3 hours 
post-injection [31]. Thus, the PET-CT results indicate 
that the 68Ga remains sufficiently well bound to the 
SERRS nanoparticles in vivo. 
To evaluate the utility of PET-SERRS NPs for 
delineating liver cancers, we injected them into a 
mouse that had been genetically engineered to 
develop hepatocellular carcinomas (HCC) [16]. 
PET-SERRS NPs (150 μL, 10 nM nanoparticles, 500 
μCi, 18.5 MBq 68Ga) were intravenously injected into 
the tail vein and PET and Cerenkov scans were 
obtained 3 h post-injection (Fig. 5A, Fig. S8). The PET 
signal exhibited several distinct filling defects 
throughout the liver, as hypothesized, suggesting the 
presence of tumors. We surgically exposed the livers 
of the cancer-bearing mouse and performed 
high-resolution SERRS scans in a simulated 
intraoperative setting. Even without SERRS contrast, 
some large tumors with sizes and locations 
corresponding to the filling defects on the PET scan 
were clearly visible. The SERRS map demonstrated 
pronounced filling defects where tumors were 
present, and correlated precisely with the 
pre-operative PET images (Fig. 5B-E). The 
co-registration of PET and SERRS signals in the liver 
indicate that the PET-SERRS nanoparticles remain 
intact after intravenous injection and circulation. To 
ensure that the PET signal corresponded with the 
healthy tissue throughout the volume of the liver, we 
also performed PET-MRI scans. The filling defects 
(i.e., negative contrast) observed via PET matched 
abnormal signal caused by the tumors on MRI, 
confirming that the PET-SERRS NPs delineate healthy 
versus cancerous tissue throughout the liver (Fig. 
6A-C).  
 
 
Figure 6. PET-MR imaging of liver cancer using PET-SERRS 
nanoparticles. A mouse with genetically engineered hepatocellular carcinoma 
(HCC) was injected with 400 µCi of 68Ga-labeled PET-SERRS NPs. After 3 
hours, micro-PET-MRI was performed, and data analysis and PET-MRI 
co-registration were completed using VivoQuantTM software (InviCro LLC, 
Boston, USA). Shown are axial sections through the upper abdomen. A) Axial 
T1-weighted MR image through the liver, demonstrating a hypointense region 
(dashed-line circle), which was later confirmed to represent a HCC on 
pathological examination. Arrowhead = gallbladder. B) PET image with a signal 
void (arrow) corresponding to the location of the HCC. C) MRI-PET overlay.  
 
Conclusion 
The stability of the PET-SERRS NPs reported 
herein, and their utility for in vivo imaging justify 
further investigation into their use as whole-body, 
combined pre- and intra-operative multimodal 
contrast agents. The PET-SERRS NPs enable 
whole-body imaging as a pre-operative roadmap and 
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intraoperative rapid hand-held SERRS scanning or 
high-resolution SERRS imaging for precise surgical 
guidance. Notably, this method is likely to work with 
a variety of other radionuclides, as observed for pure 
silica nanoparticles. Most importantly, this work 
introduces a general method for chelator-free 
radiolabeling of silica-encapsulated materials, thus 
opening many new avenues for their use in 
biomedical and other fields. Future research efforts 
will seek to improve upon the stability of the silica 
shells, such that no morphological changes are 
observed after radiolabeling. This will improve 
confidence that nanoparticle formulations with 
surface-bound species like antibodies will maintain 
their composition. 
Materials and Methods 
SERRS nanoparticle synthesis 
Gold nanoparticles were synthesized by adding 
7.5 mL 1% (w/v) sodium citrate to 1.000 L boiling 0.25 
mM HAuCl4. After the nanoparticle dispersion 
reaches the red color indicative of a complete reaction, 
it is left to cool for 30 minutes, then concentrated by 
centrifugation (10 min, 7500 x g, 4°C) and dialyzed 
overnight (3.5 kDa MWCO; 5 L 18.2 MΩ.cm). The 
dialyzed gold nanoparticles (140 μL; 2.0 nM) were 
added to 1 mL absolute ethanol in the presence of 50 
μL tetraethoxyorthosilicate (Sigma Aldrich, 99.999%), 
20 μL 28% (v/v) ammonium hydroxide (Sigma 
Aldrich) and 2 μL IR-780 dissolved in 
N,N-dimethylformamide. IR-780 was selected 
because of its resonance with the 785nm laser line, 
cationic charge, compatibility with silication, and 
consistency with our previous studies. After 25 
minutes of shaking (375 rpm) at ambient conditions in 
a plastic container, the SERRS-NPs were centrifuged, 
washed three times with ethanol, and redispersed in 
water to yield 5 nM SERRS-Nanoprobes. 
SERRS nanoparticle characterization 
Nanoparticles were imaged by transmission 
electron microscopy (TEM) acquired on carbon grids 
(Ted Pella, Inc.) using a JEOL 1200 EX microscope 
(Peabody, MA). Dispersion concentrations were 
determined by Nanoparticle Tracking Analysis (NTA; 
Nanosight, Duxbury, MA). For radiochemical yield 
and serum stability studies see supporting 
information. 
Radiolabeling protocol 
68Ga (t1/2=68 m) was eluted from a 68Ge-68Ga 
generator (ANSTO, Australia) as previously 
described [35], with 555-740 MBq (15-20 mCi) 
radioactivity per elution. 68Ga was eluted with 0.1 N 
HCl (1.5 mL), and either immediately used or trapped 
on a filter, washed, and eluted with 0.5 M KOH (0.500 
mL). The 68Ga HCl solution was neutralized with 28% 
NH4OH (13 uL) while the 68Ga hydroxide solution 
was neutralized with concentrated HCl (20-30 µL). 
Upon neutralization, 50-100 µL of 37 MBq (0.5-1.0 
mCi) 68Ga was immediately added to SERRS 
nanoparticle dispersions (10 nM, in 100 μL of 10 mM 
buffer, pH = 7.4 or pH=8.5) and incubated at 70 °C on 
a thermomixer at 500 rpm for 45 minutes. Purification 
was completed by centrifugation at 10,000 rpm for 120 
seconds, followed by decanting the supernatant and 
redispersing in buffer (e.g, 2-(N-morpholino) 
ethanesulfonic acid). 
In vivo experiments 
All animal experiments were done in accordance 
with protocols approved by the Institutional Animal 
Care and Use Committee of Memorial Sloan Kettering 
Cancer Center and followed National Institutes of 
Health guidelines for animal welfare. 
Genetically engineered hepatocellular 
carcinoma (HCC) mouse model 
To generate endogenous HCCs in mice, a sterile 
0.9% NaCl solution/plasmid mix was prepared 
containing 5 μg of DNA for the pT3 EF1a-Myc 
Sleeping-beauty transposon plasmid mixed with 
CMV-SB13 Sleeping-beauty transposase plasmid (1:5 
ratio) for each injection. A total volume of the plasmid 
mix corresponding to 10% of body weight was 
injected into the lateral tail vein of eight to ten week 
old female FVBN mice (Jackson laboratory, Ben 
Arbor, USA) in 5−7 s. The pT3 transposon vector was 
a kind gift by Dr. Xin Chen (UCSF). Approximately 7 
weeks after injection, numerous tumors were 
observed in the livers. Pathological examination 
confirmed that the tumors represented poorly 
differentiated HCCs. 
PET/CT imaging 
At predetermined time points (1h, 3h) animals 
were anesthetized with isoflurane (Baxter Healthcare, 
Deerfield, IL) and oxygen gas mixture (2% for 
induction, 1% for maintenance) and scans were then 
performed using an Inveon PET/CT scanner (Siemens 
Healthcare Global). Whole body PET static scans were 
performed recording a minimum of 50 million 
coincident events, with durations of 10-30 min. The 
energy and coincidence timing windows were 
350−750 keV and 6 ns, respectively. The image data 
were normalized to correct for non-uniformity of 
response of the PET, dead-time count losses, positron 
branching ratio, and physical decay to the time of 
injection, but no attenuation, scatter, or 
partial-volume averaging correction was applied. 
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Images were analyzed using ASIPro VMTM software 
(Concorde Micro-systems). Whole body standard low 
magnification CT scans were performed with the 
X-ray tube setup at a voltage of 80 keV and current of 
500 µA. The CT scan was acquired using 120 
rotational steps for a total of 220 degrees yielding and 
estimated scan time of 120 s with an exposure of 145 
ms per frame. 
Cerenkov luminescence imaging 
Mice were anesthetized as described previously. 
Open filters were used for optical scans. 120-300 s 
scans were completed, depending on the photon flux. 
Handheld SERRS detection 
All handheld Raman measurements were 
performed using the MiniRam Raman handheld 
scanner (B&W TEK, Inc., Newark, DE) equipped with 
a 785 nm laser.[6, 10] Raman spectra were collected 
with an acquisition time of 1 s and analyzed with 
B&WSpec 4.01.26 Software (B&W TEK).  
Fixed-microscope SERRS imaging 
All fixed Raman scans were performed using a 
Renishaw inVia Raman microscope with a 300mW 
785 nm diode laser and 1-inch charge-coupled device 
detector (1.07 cm-1 spectral resolution). The SERRS 
spectra were collected with a 5× objective (Leica) and 
the laser output measured at the objective was 100 
mW at 100% laser power. Scans were typically 
performed at 100 mW laser power, 1.5-s acquisition 
time, using the StreamLine high-speed acquisition 
mode. The Raman maps were generated by means of 
a DCLS algorithm (WiRE 3.4 software, Renishaw). 
PET-MRI 
A mouse with genetically engineered 
hepatocellular carcinoma (HCC) was injected with 
400 µCi of 68Ga-labeled PET-SERRS NPs. After 3 
hours, micro-PET-MRI was performed (T1-weighted) 
on a nanoScan PET/MRI system (Mediso USA, 
Boston, MA) and the data analysis and PET-MRI 
co-registration were completed using VivoQuantTM 
software (InviCro LLC, Boston, USA).  
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